You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TCR, solid tumor, TCR-T, neoantigen, Alaunos

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HLA Typing and Tumor Neoantigen Identification forPhase I/II

Recruiting
  • Ovarian Cancer
  • +5 more
    • Houston, Texas
      MD Anderson Cancer Center
    Jul 27, 2022

    Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer Trial in Shanghai (Fludarabine + Cyclophosphamide,

    Not yet recruiting
    • Cervical Cancer
    • +6 more
    • Fludarabine + Cyclophosphamide
    • HRYZ-T101 TCR-T Cell
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 27, 2023

    Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Houston (Neoantigen specific TCR-T cell drug product,

    Recruiting
    • Gynecologic Cancer
    • +11 more
    • Neoantigen specific TCR-T cell drug product
    • Aldesleukin (IL-2)
    • Houston, Texas
      MD Anderson Cancer Center
    Jul 27, 2022

    TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors Trial in Nanning (KSX01-TCRT injection)

    Recruiting
    • TCR-T Cells
    • +2 more
    • KSX01-TCRT injection
    • Nanning, Guangxi Zhuang Autonomous Region, China
      The first affiliated hospital of Guang Xi medical university
    Mar 31, 2023

    Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)

    Not yet recruiting
    • Solid Tumors
    • TCR-T cells
    • +4 more
    • (no location specified)
    Dec 12, 2022

    Pancreatic Cancer Trial in Guangzhou (TCR-T therapy)

    Recruiting
    • Pancreatic Cancer
    • TCR-T therapy
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital
    Aug 10, 2022

    Advanced Solid Tumor Trial in Beijing (YK0901 cells)

    Not yet recruiting
    • Advanced Solid Tumor
    • YK0901 cells
    • Beijing, China
      Department of GI Oncology, Peking University Cancer Hospital
    Jun 27, 2023

    TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors Trial in Nanning (KSH01 injection)

    Recruiting
    • TCR-T Cells
    • +2 more
    • KSH01 injection
    • Nanning, Guang XI, China
      The first affiliated hospital of Guang Xi medical university
    Sep 14, 2022

    Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)

    Withdrawn
    • Advanced Solid Tumor
    • TCRT-ESO-A2
    • (no location specified)
    Aug 31, 2022

    Solid Tumor Trial in Guangzhou (tumor-specific TCR-T cells, Interleukin-2)

    Recruiting
    • Solid Tumor
    • Guangzhou, Gaungdong, China
      Sun Yat-sen University Cancer Center
    Oct 21, 2021

    Subjects Treated With Autologous T Cells Using Sleeping Beauty

    Not yet recruiting
    • Gynecologic Cancer
    • +9 more
    • Neoantigen specific TCR-T cell drug product
    • Houston, Texas
      MD Anderson Cancer Center
    Jul 27, 2022

    Advanced Solid Tumor Trial in Bethesda, Boston (STAR0602)

    Recruiting
    • Advanced Solid Tumor
    • Bethesda, Maryland
    • +1 more
    Jan 6, 2023

    Advanced Solid Tumors Trial in Chongqing (TC-N201 cells, IL-2, Fludarabine)

    Recruiting
    • Advanced Solid Tumors
    • TC-N201 cells
    • +4 more
    • Chongqing, China
      TCRCure Biopharma Ltd.
    May 25, 2023

    Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

    Not yet recruiting
    • Malignant Epithelial Neoplasms
    • TCR-transduced T cells
    • +2 more
    • Portland, Oregon
      Providence Portland Medical Center
    Apr 22, 2022

    Nonsmall Cell Lung Cancer, Solid Tumor, Adult Trial in Guanzhou (TCR-T cells)

    Recruiting
    • Nonsmall Cell Lung Cancer
    • Solid Tumor, Adult
    • TCR-T cells
    • Guanzhou, Guangdong, China
      The Second Affiliated Hospital of Guangzhou Medical University
    Sep 19, 2021

    Solid Tumor Trial in United States (NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2)

    Suspended
    • Solid Tumor
    • NeoTCR-P1 adoptive cell therapy
    • +2 more
    • Duarte, California
    • +8 more
    Aug 16, 2022

    Solid Tumor Trial in Wuhan (Neo-T, Cyclophosphamide, Fludarabine)

    Recruiting
    • Solid Tumor
    • Neo-T
    • +3 more
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Mar 23, 2023

    Solid Tumor Trial in Shanghai (Neo-T, Cyclophosphamide, Fludarabine)

    Recruiting
    • Solid Tumor
    • Neo-T
    • +3 more
    • Shanghai, China
    • +1 more
    Mar 23, 2023

    Head Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma Trial in Scottsdale, Chapel Hill (TSC-204-A0201, TSC-204-C0702,

    Not yet recruiting
    • Head and Neck Cancer
    • +20 more
    • TSC-204-A0201
    • +4 more
    • Scottsdale, Arizona
    • +1 more
    Aug 3, 2023

    Solid Tumor, Cancer, Recurrent Solid Tumors Trial in Germany, United States (IMA201 Product, IMADetect®)

    Recruiting
    • Solid Tumor
    • +3 more
    • IMA201 Product
    • IMADetect®
    • Chicago, Illinois
    • +6 more
    Dec 28, 2021

    Advanced Solid Tumors Trial in Belgium, Germany, Spain (Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR)

    Recruiting
    • Advanced Solid Tumors
    • Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
    • Ghent, Belgium
    • +2 more
    Jun 23, 2022

    Solid Tumors Trial in Tsu (TBI-1201, Cyclophosphamide, Fludarabine)

    Completed
    • Solid Tumors
    • Tsu, Mie, Japan
      Mie University Hospital
    Jun 13, 2021

    Carcinoma, Melanoma, Bladder Cancer Trial in Chengdu (Tumor antigen-sensitized DC vaccine and their sensitized T cells

    Not yet recruiting
    • Carcinoma
    • +3 more
    • Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
    • Chengdu, Sichuan, China
      West China Hospital
    Feb 10, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

    Suspended
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    May 23, 2022

    Minimal Residual Disease in Peripheral T-cell Lymphoma

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Tumor biopsy
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Dec 19, 2022